ReviewNaunyn-Schmiedeberg's archives of pharmacology2024
Unveiling the pharmacological potential of plant triterpenoids in breast cancer management: an updated review.
Review in Naunyn-Schmiedeberg's archives of pharmacology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 1 synthesis or guideline pooled it, 37 citations in OpenAlex.
- Triterpenes in breast cancer: a systematic review of preclinical evidence in rodents.Frontiers in pharmacology · 2025Pooled it
- High yield strategies for triterpenoid biosynthesis in cell factories.Journal of microbiology (Seoul, Korea) · 2026Review
- UPLC-ESI/MS-MS-based phytochemical analysis of Schinopsis balansae leaf extract and anti-skin ageing properties supported with in silico molecular docking experiments.Scientific reports · 2026Article
- Unveiling the antidiabetic, anti-inflammatory and anti-hemolytic activities of Raphanus sativus leaves through in-vitro and in-silico studies.Scientific reports · 2026Article
- Antiproliferative Effect of 24-Deoxysericoside From Terminalia macroptera Guill. & Perr. (Combretaceae) Against Breast Carcinoma: In Vitro, Molecular Docking and ADME Assessment.Cancer reports (Hoboken, N.J.) · 2026Article
- Harnessing natural compounds and nanotechnology for miRNA-based osteosarcoma therapy.RSC advances · 2026Review
- Phytochemical profiling of Rosmarinus officinalis aerial parts and exploring its in vitro wound healing activity and network pharmacology.Scientific reports · 2026Article
- Phytochemical small molecules fromAmerican journal of translational research · 2026Review
- Mechanistic Insights into the Metabolic Pathways and Neuroprotective Potential of Pentacyclic Triterpenoids: In-Depth Analysis of Betulin, Betulinic, and Ursolic Acids.Biomolecules · 2025Review
- Is sacred animal (Asian Elephant) can be a medicinal repository: a new approach for colon cancer treatment using the methanolic extracts of the dung samples and their valuation for antimicrobial, cytotoxic, and apoptotic actions.BMC complementary medicine and therapies · 2025Article
- Article
- Zebrafish in the spotlight: expanding Frontiers in toxicology and drug discovery.Toxicology research · 2025Review
- Nutraceutical Potential of Bitter Melon (Current issues in molecular biology · 2025Review
- Comprehensive GC-MS Profiling and Multi-Modal Pharmacological Evaluations ofPharmaceuticals (Basel, Switzerland) · 2025Article
- Phytochemicals in Breast Cancer Prevention and Treatment: A Comprehensive Review.Current issues in molecular biology · 2025Review
- Advances in research on the effects of medicinal and edible substances on lung cancer: an updated review.Frontiers in pharmacology · 2025Review
- Therapeutic Potential of Underexplored Phytoconstituents Targeting Molecular Pathways in Breast Cancer Subtypes.Mini reviews in medicinal chemistry · 2025Review
- An updated review deciphering the anticancer potential of pentacyclic triterpene lupeol and its nanoformulations.Frontiers in pharmacology · 2025Review
- Clinically proven natural products against breast cancer, with mechanistic insights.Oncology research · 2025Review
- Promising and challenging phytochemicals targeting LC3 mediated autophagy signaling in cancer therapy.Immunity, inflammation and disease · 2024Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Breast cancer is the most prevalent type of cancer, the fifth leading cause of cancer-related deaths, and the second leading cause of cancer deaths among women globally. Recent research has provided increasing support for the significance of phytochemicals, both dietary and non-dietary, particularly triterpenoids, in the mitigation and management of breast cancer. Recent studies showed that triterpenoids are promising agents in the treatment and inhibition of breast cancer achieved through the implementation of several molecular modes of action on breast cancer cells. This review discusses recent innovations in plant triterpenoids and their underlying mechanisms of action in combating breast cancer within the timeframe spanning from 2017 to 2023. The present work is an overview of different plant triterpenoids with significant inhibition on proliferation, migration, apoptosis resistance, tumor angiogenesis, or metastasis in various breast cancer cells. The anticancer impact of triterpenoids may be attributed to their antiproliferative activity interfering with angiogenesis and differentiation, regulation of apoptosis, DNA polymerase inhibition, change in signal transductions, and impeding metastasis. The present review focuses on several targets, mechanisms, and pathways associated with pentacyclic triterpenoids, which are responsible for their anticancer effects. We could conclude that natural triterpenoids are considered promising agents to conquer breast cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.